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ABSTRACI 
We examined the effect of in vitro incubation with the oral gold compound au- 
ranofin (AF) on arachidonic acid (AA) release and metabolism by rat alveolar 
macrophages (AMs). AF stimulated dose- and time-dependent release of 14C-AA from 
prelabeled AMs, which reached 4.7 f 0.3% (mean f SEM) of incorporated radioactivity 
at 10 ltg/ml for 90 min, as compared to 0.5 + 0.1% release following control incubation 
for 90 min (p<O.OOl). Similar dose- and time-dependent synthesis of thromboxane 
(TX) A2 (measured as TxB2) and prostaglandin (PG) E2 was demonstrated by radioim- 
munoassay of medium from unlabeled cultures, reaching 18-fold and g-fold, respec- 
tively, of the control values at 10 pg/ml AF for 90 min (p<O.OOl for both). AF-induced 
TxB2 and PGE2 synthesis was inhibited by indomethacin as well as by pretreatment 
with methylpretiisolone. No increase in the synthesis of immunoreactive leukotrienes 
(LT) B4 or C4 was noted at any dose or time of AF. High performance liquid 
chromatographic separation of 14C-eicosanoids synthesized by prelabeled AMs 
confirmed that AF induced the release of free AA and its metabolism to cyclooxygenase, 
but not S-lipoxygenase, metabolites. The ability of AF to trigger macrophage AA 
metabolism may be relevant to the exacerbation of certain inflammatory processes which 
sometimes accompany gold therapy. 
INTRODUCTION 
Gold salts are efficacious in the treatment of rheumatoid arthritis (1) and, per- 
haps, asthma (2,3). However, they have been observed to exacerbate adjuvant arthritis 
in the rat (4), and are well-recognized to cause pneumonitis in humans (5). Because 
macrophage-derived metabolites of arachidonic acid (AA) are thought to be important in 
the pathogenesis of chronic inflammatory disorders (6) such as rheumatoid arthritis and 
asthma, and because the macrophage is a putative target cell for the anti-inflammatory 
effects of chrysotherapy (7), we have initiated studies to examine the effects of in vitro 
incubation with the oral gold compound auranofin (AF) on macrophage AA metabolism. 
In a previous study (8), we observed that therapeutic concentrations of AF inhibited 
ionophore A23 187-induced 5lipoxygenase metabolism in the rat alveolar macrophage 
(AM). However, thromboxane A2 synthesis was concomitantly augmented by AF. 
Therefore, in the present study we have examined the effect of AF alone on AA 
metabolism in the same cell. Our results indeed indicate that AF triggers dose- and time- 
dependent release of AA and its cyclooxygenase metabolites. These findings may be 
relevant to the seemingly paradoxical potential of gold compounds to exacerbate in- 
flammation. 
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METHODS 
Macrouhaue isolation and culture. Alveolar macrophages were obtained by bron- 
choalveolar lavage from respiratory disease-free 125-150 g female Wistar rats (Charles 
River, Portage, MI), as previously described (9). Two x 106 cells suspended in 
medium 199 with modified Earle’s salts (M199; GIBCO, Grand Island, NY) were 
plated in 35 x 10 mm plastic culture dishes (Falcon Plastics, Oxnard, CA) and cultured 
at 370 C in a humidified atmosphere of 5%. C@, in air. After 1 h, non-adherent cells 
were removed bv washing twice with Hanks’ balanced salt solution (HBSS: GIBCO). 
The resultant adherent cell population has been found to contain 95% ‘AMs by morpho- 
logic criteria and esterase staining (9) with viability as assessed by trypan blue exclusion 
exceeding 90%. Macrophage monolayers were then cultured overnight (16 h) in Ml99 
containing 10% heat-inactivated newborn calf serum (NCS; GIBCO) in the presence or 
absence of radiolabeled AA prior to experimental incubations. In some experiments, 
overnight incubations were carried out in the presence of 1 pM methylprednisolone 
(10). Following overnight culture, these monolayers have been found to contain ap- 
proximately 8.5 l_tg DNA (9) and 100 pg protein (11). 
Prelabelinp: of macronhaze cultures. In selected experiments, cellular lipids were prela- 
beled by including 0.2 l,tCi of [ l-I4C] AA (specific activity 54-57 mCi/mmol, Dupont- 
New England Nuclear, Boston, MA) in the medium during overnight culture (11). The 
uptake of radiolabel by macrophage cultures, determined as described previously (9), 
was 31.6 + 1.4% (mean + SEM, n=4). 
Incubations. Duplicate cultures of unlabeled or prelabeled AMs were washed twice with 
HBSS and incubated for 30. 60. or 90 min with 1 ml of Ml99 containine 0.2.5. or 10 
pg/ml AF. Auranofin (generously provided by Smith Kline & Fren&Laboratories, 
Philadelphia, PA) was prepared as a stock solution at 20 m&l in DMSO, and diluted 
directly into Ml99 to reach the desired final concentrations. All cultures contained 
DMSO at a final concentration of 0.5%. In some experiments, indomethacin (Sigma), 5 
PM in 0.05% ethanol (final concentration) was added to cultures simultaneous with AF. 
Neither viability nor eicosanoid synthesis was affected by DMSO or ethanol in the 
concentrations utilized. In selected experiments, prelabeled cultures were incubated for 
30 min with the agonist ionophore A23187 (Calbiochem-Behring Corp., La Jolla, CA), 
1 pM in 0.5% DMSO, or the detergent T&on-X 100 (Sigma), O.Ol-0.1%. 
Release of total radioactivitv and free t4C-AA, Total radioactivity released from prela- 
beled cells was determined by counting duplicate 50 t.tl aliauots of medium in 9 ml of 
ACS scintillant (Amersham Corp., Ariingion Heights, IL): To assess deacylation of 
free 14C-AA from prelabeled cells, lipids were extracted from cells plus medium with 
chloroform/methanol (2:1, w), and separated by thin layer chromatography (TLC) on 
Silica Gel 60 plates developed with hexaneldiethyl ether/acetic acid (70:30:1, v/v/v), as 
described (12). Spots migrating with authentic AA standard (Nu-chek Prep, Inc., 
Elysian, MN) were visualized by exposure to iodine vapor, cut out, eluted with 
methanol, and radioactivity quantitated by liquid scintillation spectrometry. Both total 
counts and free 14C-AA counts were expressed as a percentage of total incorporated ra- 
dioactivity. 
mof Eicosanoids were extracted from culture media of prelabeled 
or unlabeled cells using Cl8 Sep-Pak cartridges (Waters Associates, Milford, MA), and 
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a modification (11) of the method of Westcott, et. al. (13). Recoveries for this extrac- 
tion procedure, assessed using tritiated standards (Dupont-New England Nuclear) added 
to M199, were 6570% for thromboxane B2 (TxB2, the stable metabolite of TxAz), 
leukotriene C4 (LTC4), and leukouiene B4 (LTB4) (11). 
Reverse-nhase high nerformance liauid chromatoeranhv (RP-HPLC). Radiolabeled 
eicosanoids were separated by RP-HPLC with a Waters HPLC system and a Waters 5 
l.trn Bondapak Cl8 column, as previously described (10). The mobile phase, acetoni- 
trile/water/trifluoroacetic acid, was used at a 1 ml/min flow rate. Cyclooxygenase 
metabolites were eluted during an initial isocratic phase (33:67:0.1, v/v/v) and 
lipoxygenase metabolites and free AA during a stepwise gradient increase of acetonitrile 
to 1OO:O:O.l (v/v/v). The eluate was continuously monitored for UV absorbance (210 
nm for cyclooxygenase products and free AA, 280 nm for leukotrienes, and 235 nm for 
monohydroxyeicosatetraenoic acids). Eicosanoids were identified by their co-elution 
with authentic standards. One ml eluate fractions were collected and products quanti- 
tated by liquid scintillation spectrometry in 6 ml scintillant. Authentic cyclooxygenase 
metabolites were the generous gift of Dr. J. Pike (Upjohn Co., Kalamazoo, MI) and 
lipoxygenase metabolites, of Dr. J. Rokach (Merck Frosst, Inc., Quebec, Canada). 
Radioimmunoassavs. Thromboxane B2, prostaglandin E2 (PGEz), LTB4, and LTC4 
were quantitated by radioimmunoassays (RIA). Sep-Pak extracts were dried, dissolved 
in 1 ml of phosphate-buffered saline containing 0.1% gelatin, and 0.1 ml aliquots as- 
sayed in duplicate. The sources, sensitivities, and cross-reactivities of the antibodies 
employed have been described previously (14). In all cases, concentrations of im- 
munoreactive eicosanoids were corrected for recovery. 
Assessment of viabilitv bv exclusion of trvoan blue. Following control or experimental 
incubation, medium was removed and replaced with 0.05% trypan blue (Sigma) in 
normal saline. After 10 set, dye was removed by aspiration and cultures immediately 
examined under light microscopy. The percentage of cells excluding trypan blue was 
determined as the average value from 200 cells counted in each of the duplicate cultures. 
Data analvsis. All data are expressed as mean values f SEM. Viability, total radioac- 
tivity release, free 14C-AA release, and immunoreactive eicosanoids were determined in 
duplicate culture plates for each condition and the average calculated to yield a single 
data point. Unless otherwise indicated, all data represent the results from 3 individual 
experiments. The significance of differences between group means was assessed by 
one-way analysis of variance and the Newman-Keuls Multiple Range Test. In all cases, 
a p value co.05 was considered significant. 
RESULTS 
Effect of AF on release of total radioactivitv and 14C-AA. In unstimulated cultures, ap- 
proximately 1.5% of incorporated radioactivity was released into culture medium as free 
AA plus eicosanoids at all time points (Fig. 1A). No increases in release of radioactivity 
were observed with AF at 2 l.@nl. Five l,tg/ml AF induced time-dependent release of 
radioactivity, which approached statistical significance as compared to control at 60 min 
(0.05<p<O.l) and was highly significant (p<O.OOl) at 90 min. The highest dose of AF 
(10 pg/rnl) also stimulated time-dependent release of radioactivity, which reached 10.3 
f 1.5% at 90 min. 
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Fig. 1. Effect of AF on release of total radioactivity and radiolabeled AA 
from prelabeled cells. l‘@-AA prelabeled AMs were incubated for the 
indicated times in the presence or absence of AF at the concentrations 
shown. Release of total 14C radioactivity (A) and of free 14C-AA (B) were 
determined and are plotted as the percent of total incorporated radioactivity 
measured prior to the experimental incubations. Each point represents the 
mean i SEM of 3 independent experiments, each performed in duplicate. 
Since fatty acid deacylation is the initial and probably the rate-limiting step in the 
metabolism of AA (15), we quantitated free 14C-AA in cells plus medium of cultures 
incubated for various times with and without AF in various concentrations (Fig. 1B). 
Approximately 0.5% of the initial incorporated radioactivity was constitutively released 
as free AA at all time points. At 2 yg/ml AF, AA release tended to increase over time, 
reaching approximately 1% at 90 min (O.OS<p<O.l). Significant increases in AA re- 
776 DECEMBER 1966VOL. 36 NO. 6 
PROSTAGLANDINS 
lease occurred with 5 pg/ml at 60 min and 90 min (p<O.OOl vs control at both time 
points), and with 10 &ml AF at all time points, reaching 4.7 Z!I 0.3% at 90 min. 
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Effect of AF on macrophage synthesis of immunoreactive TxB2 (A) Fig. 2. 
and PGE2 (B). Unlabeled AMs were incubated for the indicated times in 
the presence or absence of AF at the concentrations shown and eicosanoids 
quantitated by RIA. Data are expressed in ng/ml (&plate) and represent the 
mean f SEM of 3 independent experiments, each performed in duplicate. 
Effect of AF on macronhage eicosanoid svnthesis. Radioimmunoassay of media from 
unlabeled cultures similarly demonstrated dose- and time-dependent synthesis of TxB2 
(Fig. 2A) and PGE2 (Fig. 2B). As compared to control cultures incubated for compa- 
rable times, these differences were highly significant (pcO.001) for 5 pg./ml AF at 90 
min and 10 pg/ml AF at both 60 and 90 min. At 10 @ml AF incubation for 90 min, 
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the maximal levels of immunoreactive TxB2 and PGE2 were 5.66 +_ 0.93 ng/ml and 
1.83 + 0.10 @ml, respectively. Of note, the TxB2:PGEz ratio also increased with AF 
stimulation from a value of approximately 1.5 in unstimulated cultures to a value of > 3 
in AMs incubated with 10 l@ml AF for 90 min. This reflected a 9-fold increase in 
PGE2 synthesis and a 1 g-fold increase in TxB2 synthesis under maximal conditions as 
compared to control conditions. 
In contrast to the marked stimulatory effects of AF on AM synthesis of TxB2 
and PGE2, no such stimulation of immunoreactive LTB4 or LTQ synthesis was 
observed at any time or dose of AF. Table 1 depicts the results of experiments utilizing 
90 min incubations, but no increase in LT synthesis was seen at shorter time points 
either. 
The effects of AF on arachidonate release and metabolism were also investigated 
by RP-HPLC analysis of radiolabeled eicosanoids released by prelabeled cells. Fig. 3 
shows RP-HPLC radioactivity elution profiles from a representative experiment in 
which AMs were incubated for 60 min with medium alone (A) or AF, 5 pg/ml (B). 
Each chromatogram represents the elution profile of eicosanoids pooled from duplicate 
culture plates. As shown, unstimulated cultures released a single peak of radioactivity 
corresponding to a small amount of free AA. In contrast, cultures stimulated with AF 
demonstrated an increased release of free AA, as well as peaks corresponding to the cy- 
clooxygenase products TxB2, PGE2, and HHT. Although small peaks corresponding 
to 15hydroxyeicosateraenoic acid (15-HETE) and 12-HETE were present, no peaks 
corresponding to the 5-lipoxygenase products LTC4, LTB4, or 5-HETE were detected. 
Table 1, Effects of AF on Macrophage 
LTB4 and LTQ synthesisa 
AF concentrationb LTB4C LTC4e 
control 0.22 + 0.04 0.24 f 0.12 
2 l&W 0.17 f 0.09 0.17 f 0.01 
5 l@rnl 0.17 f 0.06 0.13 + 0.06 
10 l@ml 0.18 f 0.08 0.10 + 0.01 
aResults are the mean f SEM from 3 independent experiments, 
each performed in duplicate. 
bAl1 incubations shown were for 90 min. 
%nmunoreactive LT values expressed in ng/ml. 
Effects of indomethacin and methvlpredniw on AF-induced e’cosanoid syn&& 
The effects of indomethacin (5 l.tM) on immunoreactive eicosanoid &nthesis induced by 
5 pg/ml AF for 60 min were examined. Indomethacin completely inhibited AF-induced 
synthesis of TxB2 (AF, 0.84 f 0.15 ngjml; AF plus indomethacin, 0.11 f 0.01 @ml) 
and PGE:! (AF, 0.33 + 0.03; AF plus indomethacin, 0.15 f 0.01) (mean + one-half the 
range, n=2). At the same time, indomethacin failed to augment synthesis of LTB4 (AF, 
0.17 f 0.02 &ml; AF plus indomethacin, 0.16 f 0.04) (mean + one-half the range, 
n=2) in cultures incubated with AF. 
In one experiment, the effect of 16 h pretreatment with the glucocorticoid 
methylprednisolone (1 l,tM) on AF-induced TxB2 synthesis was evaluated. When im- 
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munoreactive TxB2 levels were corrected for control amounts, methylprednisolone pre- 
treatment resulted in a 53% inhibition of TxB2 synthesis induced by 5 @ml AF for 60 
min (data not shown). 
Effect of AF on macrouhaee viability. Macrophage viability was preserved in both 
control cultures and cultures exposed to 2 pg/ml AF for up to 90 min (Fig. 4). At 5 
pg/ml AF, viability was reduced only at the 90 min incubation time (pcO.001 vs 90 n-tin 
control). At 10 pg/ml AF, time-related cytotoxicity was observed at incubation times of 
200 
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RP-HPLC analysis of radiolabeled eicosanoids induced by AF. Fig. 3 
Prelabeled cells were incubated for 60 min in the absence (A) or presence (B) 
of 5 pg/ml AF, after which eicosanoids were extracted and separated by RP- 
HPLC. Data represent results from pooled duplicate cultures. The retention 
times of authentic standards are indicated by arrows. 
both 60 min (pcO.005 vs 60 min control) and 90 min (p<O.OOl vs 90 min control), at 
which time only 33% of cells excluded trypan blue. 
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Relationshiu between AA release and metabolism and cvtotoxicitv induced bv AF. It 
was apparent from the foregoing results that AF had the capacity to both trigger AA 
release and cyclooxygenase metabolism, as well as to cause cytotoxicity, in AM 
cultures. In order to investigate the relationship between cell injury and AA release and 
metabolism in the AM, we related cell viability (as assessed by trypan blue exclusion), 
total release of radioactivity, and the release of free arachidonate and metabolites (by 
RP-HPLC analysis) in prelabeled cultures incubated under a variety of conditions. For 
this purpose, we examined AMs exposed to: 1) AF under both non-toxic (5 @ml for 
60 min) and toxic (50 p.g/ml for 90 min) conditions; 2) calcium ionophore A23187, a 
maximal stimulus for macrophage AA metabolism; and 3) the detergent Triton-X 100 at 
various concentrations. For each condition, the total amount of radiolabeled AA plus 
metabolites released into culture medium and eluted by RP-HPLC was expressed 
relative to the amount of 14C-AA incorporated into cells, as well as to the amount of 
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&&. Effect of AF on macrophage viability. AM cultures were incubated 
for the indicated times with either medium alone or medium containing AF 
at the concentration shown. The percent of 200 cells counted which 
excluded trypan blue is plotted. Each point represents the mean + SEM of 
3 independent experiments, each performed in duplicate. 
As demonstrated in Table 2,s I@nl AF and A23187 were respectively weak and potent 
agonists of AA metabolism in the absence of cytotoxicity. In contrast, an inverse 
relationship between viability and total release of radioactivity was observed in cultures 
exposed to high-dose AF, 0.01% Triton-X, and 0.1% Triton-X. At the high dose of 
Triton-X, virtually all cells were injured and all incorporated radioactivity released. 
However, separation of radiolabeled eicosanoids by RP-HPLC revealed that under these 
conditions of increasing toxicity, progressively smaller proportions of incorporated 
radioactivity were released into media as eicosanoids. 0.1% Triton-X, which injured 
lo-fold as many cells and released lo-fold as much total radioactivity as did A23187, 
released only one-tenth the quantity of eicosanoids as did A23187, and 













































































































































































































































































































































































































even less than the weaker agonist AF (5 l.@ml). Wh en radioactive eicosanoids were 
expressed relative to the total counts released into medium, it was apparent that with 
increasing toxicity, only a small proportion of these total counts were accounted for by 
free AA or its metabolites; presumably, the majority of these counts represent intact 14C- 
AA-containing phospholipids. Therefore, these data fail to support a simple relationship 
between membrane injury per se and the activities of phospholipase or either of the 
oxygenation enzymes. 
DISCUSSION 
The major finding of this study was that the oral gold compound AF triggered 
dose- and time-dependent release of arachidonate and its cyclooxygenase metabolites 
from cultures of rat AMs. This was demonstrated by a variety of techniques: 1) quan- 
titation of total radioactivity (AA plus metabolites) released from 14C-AA prelabeled 
cells; 2) separation and quantitation of free 14C-AA released from prelabeled cells; and 
3) quantitation by RIA of TxB2 and PGE2, the major cyclooxygenase metabolites syn- 
thesized by these cells (11). Furthermore, RP-HPLC analysis of eicosanoids synthe- 
sized by prelabeled cells confirmed that AF stimulated the release of AA and its 
metabolism via the cyclooxygenase pathway to HHT - TxB2 >PGE2. Of note, both 
RIAs and RP-HPLC analysis failed to demonstrate the synthesis of S-lipoxygenase 
metabolites by AMs incubated with AF. Inhibition of prostaglandin synthesis by 
methylprednisolone pretreatment and by indomethacin supports the assumption that AF- 
induced AA metabolism proceeds via the actions of phospholipase and cyclooxygenase, 
as expected. While Snyder and associates (16) have demonstrated the capacity of AF to 
stimulate phospholipase C activity in sonicates of a macrophage-like cell line, to our 
knowledge ours is the first report to document activation of AA metabolism by a gold 
compound in intact cells. 
The rat AM has the capacity to synthesize large amounts of the 5lipoxygenase 
products LTB4, LTC4, and 5-HETE along with cyclooxygenase products in response to 
classical agonists such as zymosan particles (10) or the calcium ionophore A23 187 (14). 
However, AF failed to trigger 5lipoxygenase metabolism despite the fact that it mobi- 
lized free AA and stimulated cyclooxygenase metabolism. This is reminiscent of our 
previous observations (14) with the sulfhydryl reactant N-ethylmaleimide. Because in 
some experimental systems cyclooxygenase inhibition can shunt free AA to lipoxyge- 
nase products (17), we examined the effect of indomethacin on AF-induced eicosanoid 
synthesis. Despite the complete inhibition of AF-induced TxB2 and PCiE2 synthesis to 
levels below control values, indomethacin did not augment LT synthesis, indicating the 
lack of substrate shunting to the 5-lipoxygenase pathway under these conditions. It is 
conceivable that AF itself could complex with or catabolize 5-lipoxygenase eicosanoids, 
thereby interfering with our ability to detect them even if synthesized. However, other 
investigators (18, 19) have previously excluded such an effect of AF on exogenously 
added LT standards, and we have similarly shown that N-ethylmaleimide did not influ- 
ence recovery of exogenous LTs added to cultures of AMs (14). We therefore conclude 
that the lack of detectable 5-lipoxygenase eicosanoids in AF-treated cultures reflects a 
lack of synthesis. In a previous study we demonstrated that AF inhibited AM 5- 
lipoxygenase metabolism stimulated by A23187 (8); this inhibition appears to be 
mediated. at least in hart. bv the denletion of intracellular ATP (unnublished results), a 
co-factor’for the 5-lipoxygenase enzyme (20). We propose that the inability of AA 
mobilized by AF to be metabolized via the 5-lipoxygenase pathway is due to the dual 
capacities of AF to both trigger AA release and inhibit the 5-lipoxygenase enzyme. 
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The increase in the ratio of TxB2: PGE2 with increasing concentrations of AF 
may reflect the facts that synthesis of PGE2 (21), but not TxB2 (22), is dependent on 
reduced glutathione, and that AF dose-dependently depletes cellular glutathione 
(unpublished results). This is further suggested by the fact that levels of LTC4, whose 
synthesis is directly dependent on the conjugation of reduced glutathione to LTA.4, but 
not levels of LTB4, declined progressively with increasing concentrations of AF. Since 
TxA2 has primarily pro-inflammatory actions (23) while PGE;! has prominent down- 
regulatory effects on leukocyte activation (23), cellular immune function (24), and 
fibrogenesis (25), the increased TxB2:PGEz ratio observed with AF treatment might 
result in a net augmentation of the inflammatory process. 
Auranofin has previously been shown to be cytotoxic for a variety of cell types 
at concentrations ranging from l-10 pg/ml (26). Our data demonstrated similar dose- 
and time-dependent cytotoxicity for AMs, as judged by the inability to exclude the vital 
dye trypan blue. In order to ascertain the possible role of cytotoxicity in the ability of 
AF to trigger AA release and mertabolism, we conducted studies of arachidonate 
metabolism and viability using a broad range of agonists and toxins. If membrane 
injury alone were capable of activating the release and subsequent metabolism of AA, 
increases in eicosanoid synthesis would have been expected to parallel the increasing 
cytotoxicity caused by 50 pg/ml AF, 0.01% Triton-X, and 0.1% T&on-X. However, 
the data in Table 2 demonstrate that this was not the case; indeed, an inverse relationship 
was observed between cytotoxicity and AA release and metabolism. The detergent 
Triton-X at O.l%, which released nearly all of the incorporated 14C-AA into the 
medium, resulted in the synthesis of only 60% the quantity of eicosanoids as did the 
weak agonist AF and 10% as much as the potent agonist A23187. Since gold 
compounds cause lung injury in humans (5), any role that cytotoxicity might play in the 
capacity of AF to trigger AA release and metabolism may in fact be germane. 
Nonetheless, the results described above, as well as the fact that clear stimulation of AA 
release and/or metabolism was observed under AF incubation conditions unassociated 
with cytotoxicity (e.g., 5 p@ml AF for 60 min and 10 pg/ml AF for 30 min), leads us 
to conclude that the agonist activity of AF is independent of its cytotoxic potential. 
Rather, it is likely that the capacity of AF to trigger arachidonate metabolism is a 
consequence of its sulfhydryl or thiol reactivity (26), as this is a property shared by a 
variety of metallic (27-29) and non-metallic (14,30) sulfhydryl-reactive compounds. 
Because macrophages are relatively enriched in their AA content as compared to 
neutrophils (31), and because they produce a diverse spectrum of cyclooxygenase and 
lipoxygenase eicosanoids (32), macrophage-derived eicosanoids have been proposed to 
play a prominent role in chronic inflammation. In the case of the AM, its significance is 
further emphasized by its strategic position as the resident effector cell of the lower res- 
piratory tract (33). For these reasons, and because gold has been shown to accumulate 
in macrophages at inflammatory sites (34), including the lung (35), AA metabolism in- 
duced by AF at therapeutic concentrations may be relevant to the pathogenesis of pneu- 
monitis which sometimes complicates the therapeutic use of gold (5), as well as the ex- 
acerbation of other inflammatory processes such as adjuvant arthritis (4). 
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